SCHEMBL5115619

SCHEMBL5115619

CCOC1Oc2c(c(=O)oc3cc(C)ccc23)C1c1c(O)c2ccc(C)cc2oc1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 4/20 0.38
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
ALDH1A1 P00352 5/20 0.35
KDM4E B2RXH2 4/20 0.35
GAA P10253 3/20 0.35
HPGD P15428 3/20 0.35
GLA P06280 3/20 0.35
CASP1 P29466 3/20 0.35
CASP7 P55210 3/20 0.35
HSD17B10 Q99714 3/20 0.35
USP2 O75604 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
ADORA3 P0DMS8 1/20 0.34
MAPT P10636 2/20 0.34
TP53 P04637 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5111977 0.89 NQO1 (0.48) NQO1ALDH1A1KDM4EHPGDCASP1
SCHEMBL5125455 0.88 TP53 (0.38) NQO1JAK2JAK1TYK2JAK3
SCHEMBL5125433 0.88 NQO1 (0.38) NQO1ALDH1A1KDM4EGAAHPGD
SCHEMBL5115962 0.87 NQO1 (0.52) NQO1ALDH1A1KDM4EGAAHPGD
SCHEMBL5114210 0.85 ALDH1A1 (0.47) NQO1ALDH1A1KDM4EGAAHPGD
SCHEMBL5120322 0.84 NQO1 (0.46) NQO1JAK2JAK1TYK2JAK3
SCHEMBL14172399 0.84 NQO1 (0.40) NQO1ALDH1A1KDM4EGAAHPGD
SCHEMBL5337199 0.82 NQO1 (0.39) NQO1ALDH1A1KDM4EGAAHPGD
SCHEMBL5119698 0.81 PRNP (0.40) NQO1ALDH1A1KDM4EGAAHPGD
SCHEMBL5125494 0.80 NQO1 (0.47) NQO1ALDH1A1KMT2AMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648902-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010007-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA- ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action CYP11B2, CYP11B1, LTC4S NQO1 60/4885JAK2 4165/4885JAK1 3537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.